Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PHGE
PHGE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PHGE News
BiomX Faces Compliance Warning from NYSE
2d ago
seekingalpha
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
5d ago
Barron's
BiomX Implements Strategic Restructuring to Drive Growth
Mar 19 2026
Newsfilter
BiomX Appoints New CEO and CFO to Drive Growth
Mar 09 2026
seekingalpha
BIOMX APPOINTS MICHAEL OSTER AS CEO AND DAVID ROKACH AS CFO TO DRIVE NEXT GROWTH STAGE
Mar 09 2026
moomoo
BiomX Shares Surge Following 19.99% Stake Acquisition
Jan 27 2026
Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
Jan 27 2026
Benzinga
BiomX Secures $3 Million in Private Placement to Advance Phage Programs
Dec 29 2025
Globenewswire
BiomX Secures $3 Million in Private Placement to Advance Phage Programs
Dec 29 2025
Newsfilter
BiomX Suspends Phase 2b Trial of BX004 for Cystic Fibrosis Due to Elevated Adverse Event Rates
Dec 09 2025
NASDAQ.COM
Crude Oil Declines by More Than 1%; Structure Therapeutics Stock Soars
Dec 08 2025
Benzinga
US Stocks Show Mixed Performance; Dow Drops More Than 100 Points
Dec 08 2025
Benzinga
HC Wainwright & Co. Confirms Buy Rating for BiomX (PHGE)
Nov 27 2025
NASDAQ.COM
BiomX Seeks FDA Approval to Resume Cystic Fibrosis Trial Following Nebulizer Device Evaluation
Nov 26 2025
Benzinga
BiomX to Proceed with Cystic Fibrosis Research Using Updated BX004 Dosing; Results Anticipated in Q2 2026
Nov 26 2025
NASDAQ.COM
Autodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading
Nov 26 2025
Benzinga
Show More News
